What are the specific side effects and contraindications of Besudil/Yilaike?

Belumosudil mesylate tablets (Belumosudil), as an innovative ROCK2 inhibitor, has shown good efficacy and tolerability in chronic graft-versus-host disease by virtue of its unique immunomodulatory mechanism. However, as a systemic immunomodulatory drug, Besudil may also bring certain side effects and medication contraindications, and it needs to be used with caution under the guidance of a professional doctor.

Judging from current clinical observations, common adverse reactions of besudil mainly include gastrointestinal reactions, fatigue, headache, elevated transaminase and mild increase in creatinine. Most of these reactions are mild to moderate and reversible, with lower systemic toxicity than traditional immunosuppressive drugs. Some patients may experience nausea, abdominal pain, or loss of appetite, which can usually be relieved by adjusting their diet or medication time. Elevated liver function indicators are items that need to be monitored, especially when other immunosuppressants or anti-infective drugs are used at the same time.

In rare cases, besudil may cause an increase in creatinine or anemia, but most are mild and do not affect the continuation of treatment. It is important to note that this drug is metabolized by the liver, so patients with severe hepatic dysfunction should use caution or have the dose adjusted. Doctors usually closely monitor hematology and liver and kidney function indicators in the early stages of treatment to prevent potential risks.

As for contraindications, it currently mainly includes those who are allergic to besudil or any of its ingredients. In addition, the safety of the drug has not been established in pregnant and lactating women and should be avoided. Because its mechanism of action involves immune regulation, patients with severe infections or active viral infections should consider taking the drug after the infection is controlled.

In terms of drug interactions, besudil is mainly metabolized byCYP3A enzyme. Therefore, combined use with strong CYP3A inhibitors or inducers may affect blood drug concentrations. Drugs such as ketoconazole and rifampicin should avoid simultaneous use. Doctors often evaluate potential drug interactions before prescribing to ensure safety.

Reference: https://www.drugs.com/pro/rezurock.html